Country: United States
Language: English
Source: NLM (National Library of Medicine)
Fosaprepitant Dimeglumine (UNII: D35FM8T64X) (Aprepitant - UNII:1NF15YR6UY)
NorthStar RxLLC
INTRAVENOUS
PRESCRIPTION DRUG
Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nauseaand vomiting associated with initial and repeat coursesof highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) Limitations of Use - Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. Pediatric use information is approved for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Fosaprepitant is contraindicated in patients: - who are hypersensitive to any component of the product Hypersensitivity reactions includinganaphylactic reactions, flushing, e
No.120 —Single-dose glass vial containing 150 mg of fosaprepitant as a white to off white lyophilized cake or powder for reconstitution. Supplied as follows:
Abbreviated New Drug Application
FOSAPREPITANT- FOSAPREPITANT INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION NORTHSTAR RXLLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE FOSAPREPITANT FOR INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR FOSAPREPITANT FOR INJECTION. FOSAPREPITANT FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2008 INDICATIONS AND USAGE Fosaprepitant for injection is a substance P/neurokinin-1 (NK ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of (1): acute and delayed nausea and vomiting associated with initial and repeat coursesof highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use (1) Fosaprepitant for injection has not been studied for treatment of established nausea and vomiting. DOSAGE AND ADMINISTRATION Recommended Dosage (2.1) Administer fosaprepitant for injection as an intravenous infusion; complete the infusion approximately 30 minutes prior to chemotherapy. Adults: 150 mg on Day 1. Administer fosaprepitant for injection on Day 1 as an intravenous infusion over 20 to 30 minutes (adults). See Full Prescribing Information for dosages of concomitantantiemetic(s). (2.1) DOSAGE FORMS AND STRENGTHS Fosaprepitant for injection: 150 mg fosaprepitant, lyophilized cake or powder in single-dose vial for reconstitution (3) CONTRAINDICATIONS Known hypersensitivity to any component of this drug. (4, 5.2) Concurrent use with pimozide. (4) WARNINGS AND PRECAUTIONS CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of fosaprepitant and concomitant drugs. (4, 5.1, 7.1, 7.2) Hypersensitivity Read the complete document